药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Alphameprodine
Inotersen
The risk or severity of QTc prolongation can be increased when Inotersen is combined with Gilteritinib.
Alphameprodine
Pipemidic acid
The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Gilteritinib.
Alphameprodine
Rufloxacin
The risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Gilteritinib.
Alphameprodine
Lidoflazine
The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Gilteritinib.
Alphameprodine
Piromidic acid
The risk or severity of QTc prolongation can be increased when Piromidic acid is combined with Gilteritinib.
Alphameprodine
Acetyldigoxin
The risk or severity of QTc prolongation can be increased when Acetyldigoxin is combined with Gilteritinib.
Alphameprodine
Lorajmine
The risk or severity of QTc prolongation can be increased when Lorajmine is combined with Gilteritinib.
Alphameprodine
Oxolinic acid
The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Gilteritinib.
Alphameprodine
Prajmaline
The risk or severity of QTc prolongation can be increased when Prajmaline is combined with Gilteritinib.
Alphameprodine
Bencyclane
The risk or severity of QTc prolongation can be increased when Bencyclane is combined with Gilteritinib.
Alphameprodine
Cibenzoline
The risk or severity of QTc prolongation can be increased when Cibenzoline is combined with Gilteritinib.
Alphameprodine
Cicletanine
The risk or severity of QTc prolongation can be increased when Cicletanine is combined with Gilteritinib.
Alphameprodine
Pilsicainide
The risk or severity of QTc prolongation can be increased when Pilsicainide is combined with Gilteritinib.
Alphameprodine
Givinostat
The risk or severity of QTc prolongation can be increased when Givinostat is combined with Gilteritinib.
Alphameprodine
Triclabendazole
The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Gilteritinib.
Alphameprodine
Temefos
The risk or severity of QTc prolongation can be increased when Temefos is combined with Gilteritinib.
Alphameprodine
Tetrahydropalmatine
The risk or severity of QTc prolongation can be increased when Tetrahydropalmatine is combined with Gilteritinib.
Alphameprodine
Prulifloxacin
The risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Gilteritinib.
Alphameprodine
CUDC-907
The risk or severity of QTc prolongation can be increased when CUDC-907 is combined with Gilteritinib.
Alphameprodine
Anisodamine
The risk or severity of QTc prolongation can be increased when Anisodamine is combined with Gilteritinib.